Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

OBJECTIVE: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. METHODS: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-bl...

詳細記述

保存先:
書誌詳細
出版年:J Neurol
主要な著者: Coelho, Teresa, Yarlas, Aaron, Waddington-Cruz, Marcia, White, Michelle K., Sikora Kessler, Asia, Lovley, Andrew, Pollock, Michael, Guthrie, Spencer, Ackermann, Elizabeth J., Hughes, Steven G., Karam, Chafic, Khella, Sami, Gertz, Morie, Merlini, Giampaolo, Obici, Laura, Schmidt, Hartmut H., Polydefkis, Michael, Dyck, P. James B., Brannagan III, Thomas H., Conceição, Isabel, Benson, Merrill D., Berk, John L.
フォーマット: Artigo
言語:Inglês
出版事項: Springer Berlin Heidelberg 2019
主題:
Original Communication
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109169/
https://ncbi.nlm.nih.gov/pubmed/31853709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-019-09671-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料